AMSBIO has announced the launch of a new, highly purified Chondroitinase ABC. This new enzyme is supplied protease-free, carrier-free and with low-endotoxin levels for use in neuroscience and regenerative medicine research.
Chondroitin Sulfate Proteoglycans (CSPGs) are involved in the inhibition of axon regeneration after various forms of damage to the Central Nervous System, including stroke or spinal cord injury.
The enzyme Chondroitinase ABC purified from Proteus vulgaris, degrades these CSPGs, and has been shown to promote functional recovery and neural regeneration.
AMSBIO’s new Chondroitinase ABC is a direct replacement for the protease-free Chondroitinase ABC formerly supplied by Seikagaku Biobusiness Corporation (and available through AMSBIO), which was discontinued by the manufacturer in 2011 as part of their broader decision to pull out of the research reagents and glycobiology biochemicals business.
See http://www.amsbio.com/brochures/ChondroitinaseABC_flyer.pdf for more details on this new enzyme, including stability study and comparison with protease-free enzyme formerly available from Seikagaku Biobusiness Corporation.